Consensus Statements on the Approach to COVID-19 Vaccine Allergy Safety in Hong Kong
- PMID: 35387010
- PMCID: PMC8974694
- DOI: 10.3389/falgy.2021.690837
Consensus Statements on the Approach to COVID-19 Vaccine Allergy Safety in Hong Kong
Abstract
Background: Mass coronavirus disease 2019 (COVID-19) vaccination to achieve herd immunity is an effective means to mitigate the current COVID-19 pandemic. Reports of COVID-19 vaccine-associated allergic reactions and lack of clear local guidance are contributing factors leading to a low vaccine acceptance rate in the community. A task force of experts from the Hong Kong Institute of Allergy (HKIA) has been formed to address current needs. Objective: To formulate a set of consensus statements (CS) on COVID-19 vaccine allergy safety (VAS) in Hong Kong. Methods: A nominated task force of experts managing patients with drug and vaccine allergies in Hong Kong formulated the CS by the Delphi method. An agreement was a priori defined as ≥80% consensus. Results: A total of 11 statements met the criteria for consensus with good overall agreement among task force members, including seven statements on pre-vaccination recommendations and four statements on vaccination and post-vaccination guidance. Individuals with a history of suspected allergic reaction to prior COVID-19 vaccination should not receive further COVID-19 vaccination, and other groups at risk of COVID-19 vaccine-associated allergic reactions have been identified. The importance of pre-vaccination and post-vaccination assessment by frontline healthcare workers and evaluation by allergists are highlighted. Conclusion: The CS provides pragmatic and timely guidance for local frontline healthcare providers on decisions regarding COVID-19 VAS.
Keywords: COVID19; Hong Kong; allergy; consensus; safety; vaccine.
Copyright © 2021 Chiang, Leung, Au, Ho, Lee, Wu, Wong and Li.
Conflict of interest statement
AW is a consultant of ALK-Abelló A/S and director of Ksena Healthcare Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
-
- Who.int. Coronavirus Disease (COVID-19) Situation Reports. Who.int. (2021). Available online at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situatio... (accessed March 14, 2021).
-
- Australasian Society of Clinical Immunology and Allergy (ASCIA) . Allergy, Immunodeficiency, Autoimmunity and COVID-19 Vaccination Position Statement. Australasian Society of Clinical Immunology and Allergy (ASCIA). (2021). Available online at: https://www.allergy.org.au/hp/papers/ascia-hp-position-statement-covid-1... (accessed March 22, 2021).
-
- Vander Leek TK, Chan ES, Connors L, Derfalvi B, Ellis AK, Upton JEM, et al. . COVID-19 vaccine testing & administration guidance for allergists/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI). Allergy Asthma Clin Immunol. (2021) 17:29. 10.1186/s13223-021-00529-2 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous